Search

Background: In recent years, cases of lung adenocarcinoma morbidity have consistently grown. OCT4 is the key gene that controls the automatic renewal of stem cells, and regulates the proliferation and differentiation of cancer stem cells. The aim of this study is to detect OCT4 expression in lung adenocarcinoma tissues, and to evaluate its relevance in the metastasis, chemotherapeutic effect, and prognosis in lung adenocarcinoma patients., Methods: Immunofluorescence method was employed to detect OCT4 expression in lung adenocarcinoma tissues. The relationship between OCT4 expression and clinical pathological indicators is examined through chi-square test. Moreover, the survival rate is calculated through the Kaplan-Meier survivorship curve. Finally, the relevance between the indicators and patient survival is estimated using Cox analysis., Results: Among the 126 tissue samples of lung adenocarcinoma, 91 showed OCT4 positive cells. OCT4 expression is closely related to metastasis and chemoresistance in lung adenocarcinoma patients, and negatively corresponds to the patients' disease-free survival and survival periods., Conclusions: OCT4 expression is related to metastasis and chemoresistance in lung adenocarcinoma patients, and thus indicates poor prognosis.

The transcriptional factor Oct-4 and Survivin are the key regulatory factors in cancer cell proliferation and mitosis. A dual cancer-specific shRNA adenovirus vector, Ad5-Dual-shRNA, targeting Oct-4 and Survivin genes was constructed by molecular cloning and recombination. After cells were infected with virus, hepatocellular carcinoma cell line EHBH-H1 was used for detecting the expression of Oct-4 and Survivin proteins by Western blotting. The viral cytotoxic effect on cancer cells was detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) reduction assay in vitro, and the inhibition effect on tumor xenografts was observed in nude mice. The results showed that the expression of Oct-4 and Survivin in cancer cell line EHBH-H1 could be silenced markedly by Ad5-Dual-shRNA. In MTT and animal experiments, Ad5-Dual-shRNA also represented much stronger anti-tumor effect on tumor growth than Ad5-Surv-shRNA and Ad5-Oct4-shRNA. From this research we can draw a conclusion that the cancer-specific adenovirus vector expressing dual-shRNA targeting Oct-4 and Survivin genes may provide us a more effective, specific and convenient gene therapy method.

Objective: To determine on the expression of prostate stem cell antigen (PCSA )and Oct-4 and detect their clinicopathological significance in benign and malignant lesions of the stomach., Methods: EnVision immunohistochemistry for assaying the expression of PSCA and Oct-4 was used in paraffin-embedded sections from specimens of primary foci (n = 58) and metastatic foci of regional lymph nodes (n = 36) of gastric cancer, peritumoral tissues (n = 20), and benign lesions of the stomach (n = 80)., Results: The positive rates of PSCA and Oct-4 were significantly higher in gastric cancer than those in peritumoral tissues and benign lesions (P<0.05 or P<0.01).The positive cases of PSCA and Oct-4 in peritumoral tissues and benign lesions showed mild- to severe-atypical hyperplasia. No difference of the positive rate of PSCA and Oct-4 was found between the primary foci and the metastatic foci of gastric cancer(P > 0.05). The positive rates of PSCA and Oct-4 were significantly lower in infiltrating depth T(1) to approximately T(2), non-metastasis of lymph nodes, metastasis of lymph nodes N1 site, and non-metastasis of distant organs than those in infiltrating depth T(3) to approximately T(4), metastasis of lymph nodes, metastasis of lymph node N(2) to approximately N(3) site, and metastasis of distant organs(P < 0.05 or P < 0.01).Conclusion The expressive levels of PSCA and Oct-4 might be related to the invasive potential, metastasis of lymph nodes, and distant organs, it suggested the expressions levels of PSCA and Oct-4 might be important markers for reflecting the biological behaviors and prognosis of gastric cancer.